2seventy bio COO Jessica Snow sells $11,363 in stock

Jessica Snow, Chief Operating Officer of 2seventy bio, Inc. (NASDAQ:TSVT), recently sold shares of the company’s common stock. The biotech company, currently valued at $256 million, has seen its stock surge 69% year-to-date, according to InvestingPro data. According to a recent SEC filing, Snow sold 2,298 shares on March 17, 2025, at the price of $4.945 per share, totaling $11,363.

This transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units. Following the sale, Snow holds 254,193 shares of 2seventy bio.

In other recent news, 2Seventy Bio , in collaboration with Bristol Myers (NYSE:BMY) Squibb, reported 2024 sales of $242 million for their drug Abecma, aligning with their guidance of $240 to $250 million. The company noted that some revenue was deferred to 2025 due to infusion delays. Despite a 23% decline in fourth-quarter Abecma sales, dropping to $59 million, the company remains optimistic about its growth potential. Citi analyst Samantha Semenkow adjusted the price target for 2Seventy Bio to $9, down from $10, while maintaining a Buy rating, citing revised revenue and expense estimates. The company’s financial position includes $184 million in cash and equivalents as of December 31, 2024, with a $9 million net cash burn in the fourth quarter.

In leadership news, 2Seventy Bio appointed Jessica Snow as the new Chief Operating Officer, effective January 6, 2025. Snow has been with the company since 2021, previously serving as Senior Vice President of Quality & Head of Operations. Her appointment is part of the company’s ongoing efforts to optimize its leadership structure. The company plans to release further details about Snow’s compensation plan in a future report. These developments come as 2Seventy Bio continues to navigate its strategic and operational initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.